Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | CD69 | Q07108 | 2/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9474040 | 0.87 | KMT2A (0.55) | POLBSMN1; SMN2L3MBTL1GLAKMT2A | |
| SCHEMBL6744642 | 0.85 | SMN1; SMN2 (0.70) | POLBSMN1; SMN2L3MBTL1GLAKMT2A | |
| SCHEMBL6743332 | 0.80 | POLB (0.62) | POLBSMN1; SMN2L3MBTL1GLAKMT2A | |
| SCHEMBL31552456 | 0.79 | SMN1; SMN2 (0.71) | POLBSMN1; SMN2L3MBTL1GLAKMT2A | |
| SCHEMBL4808600 | 0.79 | L3MBTL1 (0.66) | POLBSMN1; SMN2L3MBTL1GLAKMT2A | |
| SCHEMBL7824239 | 0.78 | KDM4E (0.60) | POLBSMN1; SMN2L3MBTL1GLAKMT2A | |
| SCHEMBL6745272 | 0.78 | SMN1; SMN2 (0.60) | POLBSMN1; SMN2L3MBTL1GLAKMT2A | |
| SCHEMBL13408063 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2L3MBTL1KMT2AMEN1ADRA1A | |
| SCHEMBL7837551 | 0.77 | KMT2A (0.61) | POLBL3MBTL1KMT2AMEN1ADRA1A | |
| SCHEMBL18702949 | 0.77 | SMN1; SMN2 (0.58) | POLBSMN1; SMN2L3MBTL1GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177190-B1 | USE OF SELECTIVE ANTAGONISTS OF THE ALPHA 1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION | RECORDATI CHEM PHARM (IT) | 2005-11-02 | — | — | EP | disclosed |
| US-6953800-B2 | Use of selective antagonists of the α1B-adrenergic receptor for improvement of sexual dysfunction | RECORDATI S.A. CHEMICAL (CH) | 2005-10-11 | — | — | US | disclosed |
| US-20020161009-A1 | Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction | RECORDATI S.A. | 2002-10-31 | — | — | US | disclosed |
| EP-1177190-A2 | USE OF SELECTIVE ANTAGONISTS OF THE ALPHA 1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 2002-02-06 | — | — | EP | disclosed |
| US-6303606-B1 | FOR THERAPY OF SEXUAL DISORDERS | RECORDATI, S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2001-10-16 | — | — | US | disclosed |
| EP-0750614-B1 | QUINAZOLINYL-AMINO DERIVATIVES HAVING ALPHA-ANTAGONIST ACTIVITY | RECORDATI CHEM PHARM (CH) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000067735-A2 | USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2000-11-16 | — | — | WO | disclosed |
| US-5798362-A | USEFUL AS ALPHA-ADRENORECEPTOR BLOCKERS; CONDENSATION | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1998-08-25 | — | — | US | disclosed |
| EP-0750614-A1 | QUINAZOLINYL-AMINO DERIVATIVES HAVING ALPHA-ANTAGONIST ACTIVITY | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1997-01-02 | — | — | EP | disclosed |
| WO-1995025726-A1 | QUINAZOLINYL-AMINO DERIVATIVES HAVING α-ANTAGONIST ACTIVITY | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1995-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161009-A1 | Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction | ADRA1B, ADRA2B, ADRB2 | POLB 2529/4885SMN1; SMN2 1423/4885L3MBTL1 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.